A phase 1 trial of imatinib mesylate in combination with daunorubicin and cytarabine for patients for c-kit positive relapsed acute myeloid leukemia (AML)

被引：0
|
作者：
Advani, Anjali S. [1 ]
Sobecks, Ronald [1 ]
Sekeres, Mikkael A. [1 ]
Copelan, Ed [1 ]
Bates, Jennifer [1 ]
Tripp, Barbara [1 ]
Salvado, August [2 ]
Kalaycio, Matt [1 ]
机构：
[1] Cleveland Clin, Leukemia Program, Cleveland, OH USA
[2] Novartis Pharmaceut, E Hanover, NJ USA
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.906.906
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
906
引用
收藏
页码：276A / 276A
页数：1
相关论文
共 50 条
  • [11] Imatinib in patients with c-kit-positive acute myeloid leukemia
    Kindler, T
    Heidel, R
    Fischer, T
    BLOOD, 2005, 105 (02) : 905 - 905
  • [12] A phase II trial of high-dose imatinib mesylate for relapsed or refractory c-kit positive and Bcr-Abl negative acute myeloid leukaemia: The AFR-15 trial
    Chevallier, Patrice
    Hunault-Berger, Mathilde
    Larosa, Fabrice
    Dauriac, Charles
    Garand, Richard
    Harousseau, Jean-Luc
    LEUKEMIA RESEARCH, 2009, 33 (08) : 1124 - 1126
  • [13] A Phase II Study of CLAG Regimen in Combination with Imatinib Mesylate in relapsed or Refractory Acute Myeloid Leukemia
    Komrokji, Rami S.
    Pinilla-Ibarz, Javier
    Yu, Daohai
    Nardelli, Lisa
    Cubitt, Christopher
    Zhao, Xiuhua
    Fernandez, Hugo F.
    List, Alan F.
    Lancet, Jeffrey E.
    BLOOD, 2011, 118 (21) : 1117 - 1117
  • [14] A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia
    Aslostovar, Lili
    Boyd, Allison L.
    Almakadi, Mohammed
    Collins, Tony J.
    Leong, Darryl P.
    Tirona, Rommel G.
    Kim, Richard B.
    Julian, Jim A.
    Xenocostas, Anargyros
    Leber, Brian
    Levine, Mark N.
    Foley, Ronan
    Bhatia, Mickie
    BLOOD ADVANCES, 2018, 2 (15) : 1935 - 1945
  • [15] Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an italian multicentric phase II study
    Piccaluga, Pier Paolo
    Malagola, Michele
    Rondoni, Michela
    Arpinati, Mario
    Paolini, Stefania
    Candoni, Anna
    Fanin, Renato
    Messa, Emanuela
    Pirrotta, Maria Teresa
    Lauria, Francesco
    Visani, Giuseppe
    Alberti, Daniele
    Rancati, Francesca
    Vinaccia, Vincenza
    Russo, Domenico
    Saglio, Giuseppe
    Baccarani, Michele
    Martinelli, Giovanni
    HAEMATOLOGICA, 2007, 92 (12) : 1721 - 1722
  • [16] A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib (MLN9708) for Relapsed/Refractory Acute Myeloid Leukemia (AML)
    Advani, Anjali S.
    Cooper, Brenda
    Elson, Paul
    Mukherjee, Sudipto
    Fensterl, Jaime
    Gerds, Aaron T.
    Caimi, Paolo F.
    Tomlinson, Ben K.
    Malek, Ehsan
    Little, Jane A.
    Rush, Mary Lynn
    Bogati, Samjhana
    Parsons, Eric
    Kane, Donna
    Carraway, Hetty E.
    Nazha, Aziz
    Hamilton, Betty K.
    Sobecks, Ronald
    Bevier, Barbara
    Goebel, Christopher
    Zimmerman, Cassie
    Nielsen, Alek D.
    Hirsch, Cassandra M.
    Maciejewski, Jaroslaw P.
    Kalaycio, Matt
    deLima, Marcos
    Jacobberger, James
    Woost, Philip
    Sekeres, Mikkael A.
    BLOOD, 2016, 128 (22)
  • [17] Phase II study of imatinib in c-kit plus relapsed/refractory AML.
    Akhtar, A
    Seiter, K
    Liu, DL
    Qureshi, A
    BLOOD, 2003, 102 (11) : 871A - 871A
  • [18] A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Bortezomib for Relapsed/Refractory Acute Myeloid Leukemia
    Advani, Anjali
    Elson, Paul
    Hsi, Eric D.
    Davis, Randall
    Kalaycio, Matt
    Sobecks, Ronald
    Copelan, Edward
    Duong, Hien K.
    Foster, Bethany
    Rush, Mary Lynn
    Farhat, Leslie
    Sekeres, Mikkael A.
    BLOOD, 2012, 120 (21)
  • [19] Phase II Study of the Combination of Clofarabine Plus Idarubicin and Cytarabine (CIA) In Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
    Naqvi, Kiran
    Ravandi, Farhad
    Kantarjian, Hagop
    Borthakur, Gautam
    Ferrajoli, Alessandra
    Thomas, Deborah A.
    Koller, Charles Asa
    Konopleva, Marina
    Byrd, Anna
    Kwari, Monica
    Faderl, Stefan
    BLOOD, 2010, 116 (21) : 464 - 465
  • [20] A phase II study of combination daunorubicin, cytarabine (Ara-c), and nilotinib (TAsigna) (DATA) in patients newly diagnosed with acute myeloid leukemia with KIT expression
    Al-Kali, Aref
    Tibes, Raoul
    Atherton, Pamela
    Palmer, Jeanne
    Alkhateeb, Hassan B. B.
    Patnaik, Mrinal
    Begna, Kebede
    Gangat, Naseema
    Hashmi, Shahrukh
    He, Rong
    Litzow, Mark
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (03) : 472 - 480
12345